achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice study rationale and protocol of dialogue background patients with type 2 diabetes have 24 times greater risk for cardiovascular morbidity and mortality than those without and this is even further aggravated if they also suffer from hypertension unfortunately less than one third of hypertensive diabetic patients meet blood pressure targets and more than half fail to achieve target hba1c values thus appropriate blood pressure and glucose control are of utmost importance since treatment sometimes fails in clinical practice while clinical trials generally suggest good efficacy data from daily clinical practice especially with regard to the use of newly developed antidiabetic and antihypertensive compounds in unselected patient populations are essential the dialogue registry aims to close this important gap by evaluating different treatment approaches in hypertensive type 2 diabetic patients with respect to their effectiveness and tolerability and their impact on outcomes in addition dialogue is the first registry to determine treatment success based on the new individualized treatment targets recommended by the ada and the easdmethods dialogue is a prospective observational german multicentre registry and will enrol 10000 patients with both diabetes and hypertension in up to 700 sites after a baseline visit further documentations are scheduled at 6 12 and 24 months there are two coprimary objectives referring to the most recent guidelines for the treatment of diabetes and hypertension 1 individual hba1c goal achievement with respect to antidiabetic pharmacotherapy and 2 individual blood pressure goal achievement with different antihypertensive treatments among the secondary objectives the rate of major cardiovascular and cerebrovascular events macce and the rate of hospitalizations are the most importantconclusion the registry will be able to gain insights into the reasons for the obvious gap between the demonstrated efficacy and safety of antidiabetic and antihypertensive drugs in clinical trials and their real world balance of effectiveness and safety